APA (7th ed.) Citation

Al‐Kali, A., Aldoss, I., Atherton, P. J., Strand, C. A., Shah, B., Webster, J., . . . Kaufmann, S. H. (2023). A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia. Cancer Medicine, 12(23), 21229. https://doi.org/10.1002/cam4.6701

Chicago Style (17th ed.) Citation

Al‐Kali, Aref, et al. "A Phase 2 and Pharmacological Study of Sapanisertib in Patients with Relapsed And/or Refractory Acute Lymphoblastic Leukemia." Cancer Medicine 12, no. 23 (2023): 21229. https://doi.org/10.1002/cam4.6701.

MLA (9th ed.) Citation

Al‐Kali, Aref, et al. "A Phase 2 and Pharmacological Study of Sapanisertib in Patients with Relapsed And/or Refractory Acute Lymphoblastic Leukemia." Cancer Medicine, vol. 12, no. 23, 2023, p. 21229, https://doi.org/10.1002/cam4.6701.